Associations of Plasma Glutamatergic Metabolites with Alpha Desynchronization during Cognitive Interference and Working Memory Tasks in Asymptomatic Alzheimer’s Disease
Author:
Leong Vincent Sonny1, Yu Jiaquan2, Castor Katherine2, Al-Ezzi Abdulhakim1ORCID, Arakaki Xianghong1ORCID, Fonteh Alfred Nji2ORCID
Affiliation:
1. Cognition and Brain Integration Laboratory, Neurosciences Department, Huntington Medical Research Institutes, Pasadena, CA 91105, USA 2. Biomarker and Neuro-Disease Mechanism Laboratory, Neurosciences Department, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
Abstract
Electroencephalogram (EEG) studies have suggested compensatory brain overactivation in cognitively healthy (CH) older adults with pathological beta-amyloid(Aβ42)/tau ratios during working memory and interference processing. However, the association between glutamatergic metabolites and brain activation proxied by EEG signals has not been thoroughly investigated. We aim to determine the involvement of these metabolites in EEG signaling. We focused on CH older adults classified under (1) normal CSF Aβ42/tau ratios (CH-NATs) and (2) pathological Aβ42/tau ratios (CH-PATs). We measured plasma glutamine, glutamate, pyroglutamate, and γ-aminobutyric acid concentrations using tandem mass spectrometry and conducted a correlational analysis with alpha frequency event-related desynchronization (ERD). Under the N-back working memory paradigm, CH-NATs presented negative correlations (r = ~−0.74–−0.96, p = 0.0001–0.0414) between pyroglutamate and alpha ERD but positive correlations (r = ~0.82–0.95, p = 0.0003–0.0119) between glutamine and alpha ERD. Under Stroop interference testing, CH-NATs generated negative correlations between glutamine and left temporal alpha ERD (r = −0.96, p = 0.037 and r = −0.97, p = 0.027). Our study demonstrated that glutamine and pyroglutamate levels were associated with EEG activity only in CH-NATs. These results suggest cognitively healthy adults with amyloid/tau pathology experience subtle metabolic dysfunction that may influence EEG signaling during cognitive challenge. A longitudinal follow-up study with a larger sample size is needed to validate these pilot studies.
Funder
National Institute of Aging HMRI and Foundation Funding
Reference69 articles.
1. Systematic Review on Resting-State EEG for Alzheimer’s Disease Diagnosis and Progression Assessment;Cassani;Dis. Markers,2018 2. Harrington, M.G., Chiang, J., Pogoda, J.M., Gomez, M., Thomas, K., Marion, S.D., Miller, K.J., Siddarth, P., Yi, X., and Zhou, F. (2013). Executive function changes before memory in preclinical Alzheimer’s pathology: A prospective, cross-sectional, case control study. PLoS ONE, 8. 3. Lloret, A., Esteve, D., Lloret, M.A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., and Monllor, P. (2019). When Does Alzheimer’s Disease Really Start? The Role of Biomarkers. Int. J. Mol. Sci., 20. 4. Memory loss in Alzheimer’s disease;Jahn;Dialogues Clin. Neurosci.,2013 5. Biomarkers in Alzheimer’s disease with a special emphasis on event-related oscillatory responses;Yener;Suppl. Clin. Neurophysiol.,2013
|
|